U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, somatic

MedGen UID:
864469
•Concept ID:
C4016032
•
Finding
Synonym: NONSMALL CELL LUNG CANCER, RESPONSE TO TYROSINE KINASE INHIBITOR IN, SOMATIC
 
OMIM®: 131550

Professional guidelines

PubMed

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.
Choo JR, Soo RA
Expert Rev Anticancer Ther 2020 Apr;20(4):233-240. Epub 2020 Mar 25 doi: 10.1080/14737140.2020.1744438. PMID: 32186215
Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.
Choo JR, Tan CS, Soo RA
Target Oncol 2018 Apr;13(2):141-156. doi: 10.1007/s11523-018-0554-5. PMID: 29423594
Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE, Gandhi L, Costa DB
Am Soc Clin Oncol Educ Book 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353. PMID: 24857124

Recent clinical studies

Etiology

Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M, Harada G, Ghanem P, Bubie A, Kiedrowski LA, Murray JC, Marrone KA, Scott SC, Houseknecht S, Falcon CJ, Evans P, Feliciano J, Hann CL, Ettinger DS, Smith KN, Anagnostou V, Forde PM, Brahmer JR, Levy B, Drilon A, Lam VK
Cancer Res Commun 2024 Mar 14;4(3):786-795. doi: 10.1158/2767-9764.CRC-24-0065. PMID: 38407352Free PMC Article
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA
J Thorac Oncol 2022 Jun;17(6):779-792. Epub 2022 Mar 21 doi: 10.1016/j.jtho.2022.02.011. PMID: 35331964Free PMC Article
Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.
Choo JR, Soo RA
Expert Rev Anticancer Ther 2020 Apr;20(4):233-240. Epub 2020 Mar 25 doi: 10.1080/14737140.2020.1744438. PMID: 32186215
SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L, Kroeze SG, Guckenberger M
Lung Cancer 2017 Apr;106:50-57. Epub 2017 Feb 6 doi: 10.1016/j.lungcan.2017.02.007. PMID: 28285694
EGFR assays in lung cancer.
Dacic S
Adv Anat Pathol 2008 Jul;15(4):241-7. doi: 10.1097/PAP.0b013e31817bf5a9. PMID: 18580100

Diagnosis

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY, Kim SM, Lim S, Lee JY, Choi SJ, Yang SD, Yun MR, Kim CG, Gu SR, Park C, Park AY, Lim SM, Heo SG, Kim H, Cho BC
Clin Cancer Res 2021 Aug 1;27(15):4397-4409. Epub 2021 Jun 3 doi: 10.1158/1078-0432.CCR-20-5026. PMID: 34083237Free PMC Article
SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L, Kroeze SG, Guckenberger M
Lung Cancer 2017 Apr;106:50-57. Epub 2017 Feb 6 doi: 10.1016/j.lungcan.2017.02.007. PMID: 28285694
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
Yasuda H, Kobayashi S, Costa DB
Lancet Oncol 2012 Jan;13(1):e23-31. Epub 2011 Jul 19 doi: 10.1016/S1470-2045(11)70129-2. PMID: 21764376
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29 doi: 10.1126/science.1099314. PMID: 15118125
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA
N Engl J Med 2004 May 20;350(21):2129-39. Epub 2004 Apr 29 doi: 10.1056/NEJMoa040938. PMID: 15118073

Therapy

RET fusions in solid tumors.
Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C
Cancer Treat Rev 2019 Dec;81:101911. Epub 2019 Oct 30 doi: 10.1016/j.ctrv.2019.101911. PMID: 31715421
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC, Riely GJ
JAMA 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058. PMID: 31454018
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
Yasuda H, Kobayashi S, Costa DB
Lancet Oncol 2012 Jan;13(1):e23-31. Epub 2011 Jul 19 doi: 10.1016/S1470-2045(11)70129-2. PMID: 21764376
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29 doi: 10.1126/science.1099314. PMID: 15118125
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA
N Engl J Med 2004 May 20;350(21):2129-39. Epub 2004 Apr 29 doi: 10.1056/NEJMoa040938. PMID: 15118073

Prognosis

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA
J Thorac Oncol 2022 Jun;17(6):779-792. Epub 2022 Mar 21 doi: 10.1016/j.jtho.2022.02.011. PMID: 35331964Free PMC Article
Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY, Kim SM, Lim S, Lee JY, Choi SJ, Yang SD, Yun MR, Kim CG, Gu SR, Park C, Park AY, Lim SM, Heo SG, Kim H, Cho BC
Clin Cancer Res 2021 Aug 1;27(15):4397-4409. Epub 2021 Jun 3 doi: 10.1158/1078-0432.CCR-20-5026. PMID: 34083237Free PMC Article
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC, Riely GJ
JAMA 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058. PMID: 31454018
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Santarpia M, Gil N, Rosell R
Expert Rev Clin Pharmacol 2015;8(4):461-77. Epub 2015 Jun 11 doi: 10.1586/17512433.2015.1055252. PMID: 26068305
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29 doi: 10.1126/science.1099314. PMID: 15118125

Clinical prediction guides

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA
J Thorac Oncol 2022 Jun;17(6):779-792. Epub 2022 Mar 21 doi: 10.1016/j.jtho.2022.02.011. PMID: 35331964Free PMC Article
Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY, Kim SM, Lim S, Lee JY, Choi SJ, Yang SD, Yun MR, Kim CG, Gu SR, Park C, Park AY, Lim SM, Heo SG, Kim H, Cho BC
Clin Cancer Res 2021 Aug 1;27(15):4397-4409. Epub 2021 Jun 3 doi: 10.1158/1078-0432.CCR-20-5026. PMID: 34083237Free PMC Article
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC, Riely GJ
JAMA 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058. PMID: 31454018
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29 doi: 10.1126/science.1099314. PMID: 15118125
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA
N Engl J Med 2004 May 20;350(21):2129-39. Epub 2004 Apr 29 doi: 10.1056/NEJMoa040938. PMID: 15118073

Recent systematic reviews

Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.
Priantti JN, Fujiwara Y, Aquino de Moraes FC, Michelon I, Castro C, Leighl NB, Cavalcante L, Addeo A, Bar J, Horita N, Cortellini A, Nassar AH, Vilbert M, Naqash AR
JCO Precis Oncol 2024 Nov;8:e2400331. Epub 2024 Nov 22 doi: 10.1200/PO.24.00331. PMID: 39576954
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS, Kwon JW, Shin S, Kim HS, Kim H
J Clin Pharm Ther 2015 Dec;40(6):661-71. Epub 2015 Nov 17 doi: 10.1111/jcpt.12332. PMID: 26573867
Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.
Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S
Clin Cancer Res 2010 Jan 1;16(1):291-303. Epub 2009 Dec 22 doi: 10.1158/1078-0432.CCR-09-1660. PMID: 20028749
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S
Lancet Oncol 2008 Oct;9(10):962-72. Epub 2008 Sep 17 doi: 10.1016/S1470-2045(08)70206-7. PMID: 18804418

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • OMIM
      Related records in OMIM
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed
    • PubMed (OMIM)
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...